Ubs Group Ag Anebulo Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Anebulo Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 144 shares of ANEB stock, worth $358. This represents 0.0% of its overall portfolio holdings.

Number of Shares

144

Holding current value

$358

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$2.34 - $3.0 $336 - $432	144 New	144 $0
Q4 2022 Feb 08, 2023	SELL	$2.2 - $3.39 $2,387 - $3,678	-1,085 Reduced 39.01%	1,696 $4,000
Q3 2022 Nov 10, 2022	SELL	$2.81 - $5.49 $359 - $702	-128 Reduced 4.4%	2,781 $8,000
Q2 2022 Aug 10, 2022	BUY	$2.7 - $7.15 $2,033 - $5,383	753 Added 34.93%	2,909 $15,000
Q1 2022 May 16, 2022	BUY	$6.0 - $7.7 $9,456 - $12,135	1,576 Added 271.72%	2,156 $15,000

Q4 2021 Feb 14, 2022	SELL	$5.84 - $7.3 $1,565 - $1,956	-268 Reduced 31.6%	580 $4,000
Q3 2021 Nov 15, 2021	BUY	$6.55 - $7.77 $4,021 - $4,770	614 Added 262.39%	848 $6,000
Q2 2021 Aug 13, 2021	BUY	$6.58 - $8.95 $1,539 - $2,094	234 New	234 $2,000

Others Institutions Holding ANEB

# of Institutions

Shares Held

7.31M

Call Options Held

Put Options Held

View Full List

About Anebulo Pharmaceuticals, Inc.

Ticker ANEB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,633,200
Market Cap $63.8M
Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...

More about ANEB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account